Danaher (NYSE:DHR) Rating Reiterated by Royal Bank of Canada

Danaher (NYSE:DHR)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank of Canada in a report released on Friday, Benzinga reports. They currently have a $300.00 price target on the conglomerate’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 11.45% from the stock’s current price.

A number of other research analysts have also issued reports on DHR. Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Bank of America boosted their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Leerink Partners boosted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Barclays boosted their price target on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Finally, TD Cowen boosted their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Stock Performance

NYSE DHR traded up $4.46 during trading on Friday, reaching $269.17. The company’s stock had a trading volume of 118,798 shares, compared to its average volume of 2,772,358. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market cap of $199.37 billion, a price-to-earnings ratio of 45.52, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher has a twelve month low of $182.09 and a twelve month high of $281.70. The business’s fifty day moving average price is $260.98 and its 200-day moving average price is $255.61.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business posted $2.05 earnings per share. The business’s revenue was down 2.9% compared to the same quarter last year. As a group, analysts anticipate that Danaher will post 7.59 EPS for the current fiscal year.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 over the last quarter. Corporate insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

Institutional investors and hedge funds have recently modified their holdings of the company. Tsfg LLC lifted its stake in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the period. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter worth approximately $25,000. Cape Investment Advisory Inc. acquired a new position in Danaher during the fourth quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher during the first quarter worth approximately $30,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.